Abstract
Podophyllotoxins, including epipodophyllotoxin derivatives, can act on a diverse array of drug targets in cancer cells and thus possess potent activity against various forms of cancer cell lines, including drug-resistant forms. Moreover, several podophyllotoxin derivatives represented by etoposide and teniposide, have already been approved for cancer therapy, demonstrating podophyllotoxin moiety as a useful pharmacophore for the discovery of novel anticancer agents. This review reports the recent advances in the exploitation of podophyllotoxin derivatives to fight against multidrug-resistant cancer cells. The mechanism of action and structure-activity relationship (SAR) studies are also highlighted.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
